Fragmento

Chronic Obstructive Pulmonary Disease (COPD) represents a growing global public health problem and according to the World Health Organization, it is projected to be the third leading cause of death by 2020. The specific pattern of inflammation in COPD is characterized by a predominance of CD8+ macrophages and neutrophils; cells that are less responsive to steroids tan CD4+ lymphocytes encountered in patients with asthma. Currently steroids are the most widely used anti-inflammatory agents in patients with COPD. Roflumilast is a Phosphodiesterase-4 Enzyme inhibitor, an FDA approved (Feb 2011) oral anti-inflammatory agent which serves as an adjunct to bronchodilator therapy in the maintenance treatment of severe COPD associated with chronic bronchitis and increased risk of exacerbations.

Palabras clave:

2013-03-06   |   439 visitas   |   Evalua este artículo 0 valoraciones

Vol. 6 Núm.3. Julio-Septiembre 2012 Pags. 87 Arch Salud Sin 2012; 6(3)